[go: up one dir, main page]

HK1138260A1 - N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation - Google Patents

N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation Download PDF

Info

Publication number
HK1138260A1
HK1138260A1 HK10104304.1A HK10104304A HK1138260A1 HK 1138260 A1 HK1138260 A1 HK 1138260A1 HK 10104304 A HK10104304 A HK 10104304A HK 1138260 A1 HK1138260 A1 HK 1138260A1
Authority
HK
Hong Kong
Prior art keywords
mmol
nmr
mhz
added
dmso
Prior art date
Application number
HK10104304.1A
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
HK1138260B (en
Inventor
Ajay Purohit
Thomas D. Harris
Heike S. Radeke
Simon P. Robinson
Ming Yu
David S. Casebier
Michael T. Azure
Original Assignee
Lantheus Medical Imaging, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging, Inc. filed Critical Lantheus Medical Imaging, Inc.
Publication of HK1138260A1 publication Critical patent/HK1138260A1/en
Publication of HK1138260B publication Critical patent/HK1138260B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/70Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/06Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (4)

  1. Verbindung zur Verwendung als bilddarstellendes Mittel mit der folgenden Struktur:
  2. Hydrochloridsalz einer Verbindung nach Anspruch 1 mit der Struktur: N-[3-Brom-4-(3-[18F]fluorpropoxy)-benzyl]guanidinhydrochlorid.
  3. Verfahren zur bildlichen Darstellung der Innervation des Herzens, bei dem man: einem Patienten eine wirksame Menge der Verbindung nach einem der vorhergehenden Ansprüche verabreicht, die von der Verbindung emittierte Strahlung nachweist und daraus ein Abbild darstellt.
  4. Zusammensetzung zur bildlichen Darstellung, umfassend eine Verbindung nach Anspruch 1 oder 2 und einen oder mehrere Hilfsstoffe.
HK10104304.1A 2006-12-26 2007-12-21 N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation HK1138260B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87721106P 2006-12-26 2006-12-26
US60/877,211 2006-12-26
PCT/US2007/088500 WO2008083056A2 (en) 2006-12-26 2007-12-21 Ligands for imaging cardiac innervation

Publications (2)

Publication Number Publication Date
HK1138260A1 true HK1138260A1 (en) 2010-08-20
HK1138260B HK1138260B (en) 2013-09-19

Family

ID=

Also Published As

Publication number Publication date
KR101718160B1 (ko) 2017-03-20
IL224396B (en) 2018-04-30
TW201628660A (zh) 2016-08-16
EP2474525A3 (de) 2012-07-25
CN101687780B (zh) 2016-01-20
ES2405655T3 (es) 2013-05-31
JP6021860B2 (ja) 2016-11-09
US8491868B2 (en) 2013-07-23
CO6231002A2 (es) 2010-12-20
DK2474523T3 (da) 2020-07-13
US20180339070A1 (en) 2018-11-29
CN105622463A (zh) 2016-06-01
IL253885A0 (en) 2017-10-31
EP2114873B1 (de) 2013-02-20
BRPI0722082A2 (pt) 2014-04-01
ES2804801T3 (es) 2021-02-09
DK2474525T3 (da) 2020-07-13
TWI618544B (zh) 2018-03-21
US20250161500A1 (en) 2025-05-22
EP2474526A2 (de) 2012-07-11
EP2474526A3 (de) 2012-07-25
CN105622463B (zh) 2019-02-22
ES2805286T3 (es) 2021-02-11
RU2506256C2 (ru) 2014-02-10
CN101687780A (zh) 2010-03-31
CA2984226C (en) 2021-02-23
MX367292B (es) 2019-08-13
US11241509B2 (en) 2022-02-08
EP2474523B1 (de) 2020-04-08
JP2016183164A (ja) 2016-10-20
WO2008083056A2 (en) 2008-07-10
US20220288243A1 (en) 2022-09-15
US20140030189A1 (en) 2014-01-30
KR101810348B1 (ko) 2017-12-18
CN110003079A (zh) 2019-07-12
KR20160049044A (ko) 2016-05-04
PT2114873E (pt) 2013-05-06
JP2014237679A (ja) 2014-12-18
ZA200904828B (en) 2014-12-23
MX2009007018A (es) 2009-11-26
EP2474524A3 (de) 2012-07-18
TW200848078A (en) 2008-12-16
US10010631B2 (en) 2018-07-03
EP2474523A3 (de) 2012-07-18
AU2007339954A1 (en) 2008-07-10
SG177918A1 (en) 2012-02-28
IL199563A (en) 2017-08-31
JP5656408B2 (ja) 2015-01-21
EP2114873A2 (de) 2009-11-11
EP2474525A2 (de) 2012-07-11
EP2474524A2 (de) 2012-07-11
KR20170102580A (ko) 2017-09-11
PL2114873T3 (pl) 2013-08-30
BRPI0722082A8 (pt) 2018-03-13
RU2009128591A (ru) 2011-02-10
US20100221182A1 (en) 2010-09-02
JP2010514786A (ja) 2010-05-06
CA2673853C (en) 2017-10-31
WO2008083056A3 (en) 2009-04-30
KR20140140134A (ko) 2014-12-08
KR20090097946A (ko) 2009-09-16
EP2474523A2 (de) 2012-07-11
US12324845B2 (en) 2025-06-10
TWI549692B (zh) 2016-09-21
CA2984226A1 (en) 2008-07-10
AU2007339954B2 (en) 2013-06-20
EP2474525B1 (de) 2020-04-15
DK2114873T3 (da) 2013-05-13
CA2673853A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
US20250161500A1 (en) Ligands for imaging cardiac innervation
HK1138260B (en) N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation
HK1173430A (en) Ligands for imaging cardiac innervation
HK1173429B (en) Ligands for imaging cardiac innervation
HK1173430B (en) Ligands for imaging cardiac innervation
HK1173429A (en) Ligands for imaging cardiac innervation
HK40011061A (en) Ligands for imaging cardiac innervation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231221